Significant publications on infectious diseases pharmacotherapy in 2010

American Journal of Health-System Pharmacy

Volumn 68, Issue 21, 2011, Pages 2075-2085

  Hirsch, Elizabeth B ^a   Cottreau, Jessica M ^a   Ikwuagwu, Judy O ^b   Lusardi, Katherine T ^a,c   Mohr, John F ^d   Rodriguez, Sarah M ^e   Shah, Dhara N ^a   Tran, Truc T ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b Texas and the Task Force on the ACGME Competencies   (United States)

^c CARDINAL HEALTH   (United States)

^d CUBIST PHARMACEUTICALS INC   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acquired immunodeficiency syndrome; Antinfective agents; Communicable diseases; Data collection; HIV infections; Journals; Organizations; Peer review; Pharmacists; Protocols; Publications

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM; CEFEPIME; COLISTIN; GLUTAMATE DEHYDROGENASE; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TENOFOVIR; VANCOMYCIN;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BACTERIUM DETECTION; CATHETER INFECTION; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG THERAPY; EARLY INTERVENTION; ENTEROBACTER CLOACAE; HAND WASHING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; INDIA; INFECTION; INFECTIOUS DISEASE MEDICINE; KLEBSIELLA PNEUMONIAE; MEGACOLON; MULTIDRUG RESISTANT GRAM NEGATIVE BACTERIAL INFECTION; OUTCOME ASSESSMENT; PAKISTAN; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEPSIS; SHOCK; STENOTROPHOMONAS MALTOPHILIA; SURVIVAL RATE; UNITED KINGDOM; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 80455162525     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110125     Document Type: Article

References (25)

1. Yeh RF, Kuper KM, Coyle EA et al. Significant publications on infectious diseases pharmacotherapy in 2007. Am J Health-Syst Pharm. 2008; 65:e72-9.
2. Kuper KM, Hirsch EB, Tam VH. Significant publications on infectious diseases pharmacotherapy in 2008. Am J Health-Syst Pharm. 2009; 66:1726-34.
3. Palmer HR, Cottreau JM, Garey KW et al. Significant publications on infectious diseases pharmacotherapy in 2009. Am J Health-Syst Pharm. 2010; 67:e34-42.
4. Gerding DN, Johnson S, Peterson LR et al. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol. 1995; 16:459-77.
5. Zar FA, Bakkanagari SR, Moorthi KM et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007; 45:302-7. (Pubitemid 47101025)
6. Louie T, Gerson M, Grimard D et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea (CDAD). Paper presented at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2007 Sep.
7. Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006; 34:1589-96. (Pubitemid 43810035)
8. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005; 49:3640-5. (Pubitemid 41233011)
9. Rattanaumpawan P, Lorsutthitham P, Ungprasert P et al. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by gram-negative bacteria. J Antimicrob Chemother. 2010; 65:2645-9.
10. Korbila IP, Michalopoulos A, Rafailidis PI et al. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect. 2010; 16:1230-6.
11. Kumar A, Ellis P, Arabi Y et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009; 136:1237-48.
12. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in gram-negative bacteremia? A meta-analysis. Lancet Infect Dis. 2004; 4:519-27. (Pubitemid 39077923)
13. Paul M, Benuri-Silbiger I, Soares-Weiser K et al. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ. 2004; 328:884.
14. Canton R, Coque TM. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol. 2006; 9:466-75.
15. Harish BN, Menzes GA, Shekatkar S et al. Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae from blood culture. J Med Microbiol. 2007; 56:999-1000. (Pubitemid 47047498)
16. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009; 9:228-36.
17. Yong D, Toleman MA, Giske CG et al. Characterization of a new metallo-β-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009; 53:5046-54.
18. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007; 44:357-63. (Pubitemid 46147617)
19. Patel N, Scheetz MH, Drusano GL et al. Identification of optimal renal dosage adjustments for traditional and extendedinfusion piperacillin-tazobactam dosing regimens in hospitalized patients. Antimicrob Agents Chemother. 2010; 54:460-5.
20. Kim A, Sutherland CA, Kuti JL et al. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion? Pharmacotherapy. 2007; 27:1490-7. (Pubitemid 350060204)
21. Wisplinghoff H, Bischoff T, Tallent SM et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004; 39:309-17. (Pubitemid 39050477)
22. Hirsch EB, Tam VH. Impact of multi-drug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcome Res. 2010; 10:441-51.
23. Kugelberg E, Lofmark S, Wretlind B et al. Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa. J Antimicrob Chemother. 2005; 55:22-30. (Pubitemid 40192610)
24. Hocquet D, Berthelot P, Roussel-Delvallez M et al. Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrob Agents Chemother. 2007; 51:3531-6.
25. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP et al. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One. 2010; 5:e931.